Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Head and Neck Tumors Clear all
Terminated Phase 2 Interventional Results available

Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer

NCT03938337
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cohort 1 Not Previously Treated, Cohort 2 Treated Previously
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jun 26, 2026, 2:14 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

MicroRNA Markers in Head and Neck Cancers

NCT04305366
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Tissue collection
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 26, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies

NCT04003051
View directory record Official record
Conditions
Throat Carcinoma
Interventions
Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Fort Worth, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 26, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

NCT05491512
View directory record Official record
Conditions
HPV, Throat Cancer, Oropharyngeal Carcinoma, Oropharyngeal Cancer, Human Papilloma Virus
Interventions
18 F-FMISO PET/CT, Radiation, Cisplatin, Carboplatin, 5-fluorouracil
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 26, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

NCT00392665
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Bevacizumab, erlotinib, Sulindac
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jun 26, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

Use of Cone Beam Kilovoltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00358007
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
PTV Reduction
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck

NCT02792322
View directory record Official record
Conditions
Oropharyngeal Neoplasms, Head and Neck Cancer
Interventions
Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

NCT02499328
View directory record Official record
Conditions
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 26, 2026, 2:14 AM EDT
Terminated No phase listed Observational

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

NCT01114256
View directory record Official record
Conditions
Head and Neck Cancer, Breast Cancer, Head and Neck Cancers, Non-Hodgkin Lymphoma, Colorectal Adenocarcinoma
Interventions
FNA Biopsy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Jun 26, 2026, 2:14 AM EDT
Completed No phase listed Observational

Hashimotos Thyroiditis and Thyroid Cancer

NCT01428167
View directory record Official record
Conditions
Thyroid Cancer, Hashimotos Thyroiditis
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

NCT03000257
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Venetoclax, Rovalpituzumab Tesirine, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
5
States / cities
La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Jun 26, 2026, 2:14 AM EDT
Terminated Phase 1 Interventional

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

NCT01528137
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
talactoferrin, laboratory biomarker analysis
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Jun 26, 2026, 2:14 AM EDT
Recruiting No phase listed Observational

Oropharynx (OPX) Biomarker Trial

NCT06356272
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Head and Neck Carcinoma, Head and Neck Neoplasm, Salivary Gland Neoplasms, Thyroid Gland Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 26, 2026, 2:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers

NCT02994069
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Cancer
Interventions
Cisplatin, XRT
Drug · Radiation
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

NCT02578641
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
autologous EBV specific Cytotoxic T cells, combination IV gemcitabine and IV carboplatin (AUC2)
Biological · Drug
Lead sponsor
Tessa Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
7
States / cities
Duarte, California • Sacramento, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jun 26, 2026, 2:14 AM EDT
Not listed Not applicable Interventional

Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery

NCT04963972
View directory record Official record
Conditions
Malignant Abdominal Neoplasm, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm
Interventions
Behavioral Intervention, Best Practice, Questionnaire Administration
Behavioral · Other
Lead sponsor
Lucid Lane, Inc
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

NCT01334177
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis, pharmacogenomic studies
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)

NCT00095875
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
carboplatin, cisplatin, docetaxel, fluorouracil
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
14
States / cities
La Jolla, California • Denver, Colorado • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

NCT00276523
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Jun 26, 2026, 2:14 AM EDT
Recruiting Phase 1 Interventional

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

NCT04892303
View directory record Official record
Conditions
Recurrent Thyroid Cancer
Interventions
Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)
Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jun 26, 2026, 2:14 AM EDT
Terminated Not applicable Interventional

Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer

NCT01053546
View directory record Official record
Conditions
Head and Neck Cancer, Stage I Hypopharyngeal Cancer, Stage I Laryngeal Cancer, Stage I Oropharyngeal Cancer, Stage II Hypopharyngeal Cancer, Stage II Laryngeal Cancer, Stage II Oropharyngeal Cancer, Stage III Hypopharyngeal Cancer, Stage III Laryngeal Cancer, Stage III Oropharyngeal Cancer, Stage IV Hypopharyngeal Cancer, Stage IV Laryngeal Cancer, Stage IV Oropharyngeal Cancer
Interventions
exercise intervention, questionnaire administration, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jun 26, 2026, 2:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

NCT05838729
View directory record Official record
Conditions
Head Neck Cancer, Intratumoral Injection
Interventions
RiMO-301
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 26, 2026, 2:14 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

NCT07462377
View directory record Official record
Conditions
Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR
Interventions
EPI-326
Drug
Lead sponsor
EpiBiologics
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Los Angeles, California • East Brunswick, New Jersey • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 26, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577
View directory record Official record
Conditions
Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions
177Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jun 26, 2026, 2:14 AM EDT